N@N

PIP, OIL, USO, AMRI, BABY Are Seasonally Ripe To Go Down In the Next Five Weeks

December 30, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PHARMATHENE INC (AMEX:PIP), IPATH GOLDMAN SACHS CRUDE (NYSE:OIL), United States Oil Fund LP (NYSE:USO), ALBANY MOLECULAR RESEARCH (NASDAQ:AMRI), NATUS MEDICAL INC (NASDAQ:BABY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     PIP        PHARMATHENE INC                     -11.84%             66.67% (4 of 6)         Friday, January 13th 2012
     OIL        IPATH GOLDMAN SACHS CRUDE           -6.77%              100.00% (5 of 5)        Thursday, January 26th 2012
     USO        United States Oil Fund LP           -5.79%              100.00% (5 of 5)        Tuesday, February 7th 2012
     AMRI       ALBANY MOLECULAR RESEARCH           -13.80%             81.82% (9 of 11)        Thursday, February 2nd 2012
     BABY       NATUS MEDICAL INC                   -5.23%              90.00% (9 of 10)        Thursday, January 5th 2012

PHARMATHENE INC (AMEX:PIP) - PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Its product candidates include SparVax, a recombinant protective antigen (rPA) anthrax vaccine to protect against inhalation anthrax that has completed one Phase I and two Phase II clinical trials; and Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax, which has completed Phase I clinical trial. The companys product candidates also include Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. In addition, its product candidates include RypVax, a recombinant plague vaccine comprising separate recombinant F1 (rF1) and V (rV) antigens produced in Escherichia coli, which completed three Phase I human clinical trials; and rPA anthrax vaccine, which does not require refrigeration. The companys customers include National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the U.S. National Institutes of Health. It has a collaboration agreement with Medarex, Inc. to develop and commercialize Valortim. PharmAthene, Inc. was founded in 2001 and is based in Annapolis, Maryland.

IPATH GOLDMAN SACHS CRUDE (NYSE:OIL) - Barclays Bank PLC iPath Exchange Traded Notes Linked to Goldman Sachs Crude Oil

United States Oil Fund LP (NYSE:USO) - UNITED STATES OIL FD

ALBANY MOLECULAR RESEARCH (NASDAQ:AMRI) - Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States, Europe, and Asia. The company offers drug discovery services, including assay development and design; screening programs, which provide tools to identify active compounds during the lead discovery phases of drug discovery; screening libraries for screening and hit-to-lead programs; bioanalytical services for extraction and quantitation of drug and metabolites in biological fluids and tissues; and natural product services. Its drug discovery services also include medicinal chemistry; computer-aided drug discovery services to identify novel hits or leads against selected therapeutic targets, as well as to support medicinal chemistry lead optimization programs; and in vitro ADMET assays to evaluate and improve metabolism, bioavailability, pharmacology, and toxicology of compounds. The company also provides chemical development services, such as process research and development; custom synthesis; process safety assessment; high potency and controlled substances; preparative chromatography; IND support services; fermentation development and optimization; and building blocks collection and database, as well as offers chemical synthesis and manufacturing services in accordance with cGMP regulations, and formulation services. In addition, it provides analytical services, including impurity identification and structure elucidation; method development, qualification, and validation; preformulation and physical characterization; quality control; stability services; and regulatory support, as well as offers chemical synthesis and manufacturing services. The company also serves agricultural and fine chemical companies, contract chemical manufacturers, government research entities, and non-profit organizations. Albany Molecular Research was founded in 1991 and is based in Albany, New York.

NATUS MEDICAL INC (NASDAQ:BABY) - Natus Medical Incorporated develops, manufactures, and markets neurodiagnostic and newborn care products worldwide. It provides healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The companys product offerings include neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems and phototherapy devices for the treatment of jaundice in newborn; head-cooling products for the treatment of brain injury in newborns; and software systems for managing and tracking disorders and diseases. The companys newborn hearing screening products consist of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners, as well as hearing screening supply products that are used with newborn hearing screening devices; diagnostic hearing assessment products comprise the Navigator Pro system, the Scout Sport diagnostic device, the HINT PRO, the AuDX PRO, and the Cochlea-Scan to identify abnormalities affecting the peripheral and central auditory nervous systems; and diagnostic hearing supply products. Natus Medical also offers monitoring systems, balance and mobility products, and jaundice management products. In addition, the company offers medical devices, including photometers, radiometers, patient warming lamps, neonatal heatshields, pediatric scales, blanket warming cabinets, exam lights, oxygen hoods, and newborn circumstraints; disposable supplies, which include neonatal noise attenuators, phototherapy eye masks, restraining boards, and x-ray shields; and newborn screening data management products. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. The company was founded in 1987 and is headquartered in San Carlos, California.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641